Abstract:Objective: Based on the clear role for glucagon in the pathogenesis of diabetes, glucagon-blocking therapies have been pursued as a therapeutic strategy for this disease. Here, we used REMD 2.59, a human antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb), to clarify the effects of GCGR mAb in promoting pancreatic β cell regeneration in type 2 diabetes (T2D), and its potential mechanism. Methods: GCGR mAb was administrated weekly for 4 weeks in db/db mice and HFD/STZ-induced T2D mice, including different lineage-tracing mice. The plasma insulin and glucagon were determined by using ELISA. The evaluation of islet morphology was performed with immunofluorescent analysis. GCGR mAb was also treated in the systemic Fgf21 gene knockout (Fgf21-/-) and hepatocyte-specific Fgf21 gene knockout (Fgf21Hep-/-) T2D mice. Results: Treatment with GCGR mAb lowered blood glucose, improved glucose tolerance, and elevated plasma glucagon and insulin levels in both db/db mice and HFD/STZ-induced T2D mice. The β cell dedifferentiation as indicated by β cell lineage-tracing was blocked by GCGR mAb. The β cell proliferation as indicated by insulin+ and BrdU+ cells was boosted by GCGR mAb. The α-to-β cell conversion, as evaluated by glucagon+ insulin+ cells and confirmed by α cell lineage-tracing, was facilitated by GCGR mAb. After GCGR mAb treatment, some insulin+ cells were located in the duct region or even colocalized with duct cell markers, suggestive of duct-derived β cell neogenesis that was also verified by Ngn3+ cell lineage-tracing. Notably, GCGR mAb could still improve glucose tolerance and increase β cell mass, but these effects were attenuated in Fgf21-/- and Fgf21Hep-/- T2D mice compared with WT T2D mice. Conclusions: GCGR mAb promotes β cell regeneration via inhibiting β cell dedifferentiation and promoting β cell self-replication, α-to-β cell conversion and duct-derived β cell neogenesis in T2D mice, which is partly mediated by liver-derived FGF21. Disclosure X. Cui: None. T. Wei: None. J. Feng: None. J. Yang: None. H. Yan: Board Member; Self; REMD Biotherapeutics, Other Relationship; Spouse/Partner; REMD Biotherapeutics. R. Wei: None. T. Hong: Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp., Novo Nordisk, Sanofi. Funding National Natural Science Foundation of China (81830022)

Glucagon receptor monoclonal antibodies: A new strategy for diabetes pharmacotherapy

Glucagon Receptor Antagonist Upregulates Circulating GLP-1 Level by Promoting Intestinal L-cell Proliferation and GLP-1 Production in Type 2 Diabetes

Glucagon Receptor Antagonism Promotes the Production of Gut Proglucagon-Derived Peptides in Diabetic Mice.

Antagonistic Glucagon Receptor Antibody Promotes Α-Cell Proliferation and Increases Β-Cell Mass in Diabetic Mice

An emerging direction in glucagon-based therapy

Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic Β-Cell Regeneration in Situ in Type 1 Diabetic Mice

Hepatic Glucagon Receptor Binding and Glucose-Lowering in Vivo by Peptidyl and Non-Peptidyl Glucagon Receptor Antagonists.

Glucagon Switches between GLP-1 and Glucagon Receptors in Normal and Hyperglycemic Mice

Anti-diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist.

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose

Glucagon Potentiates Insulin Secretion Via Beta-Cell Gcgr At Physiological Concentrations Of Glucose

115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

Targeting GLP-1 receptor trafficking to improve agonist efficacy

A GLP‐1/glucagon/CCK‐2 receptors tri‐agonist provides new therapy for obesity and diabetes

Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

Non‐peptide agonists and positive allosteric modulators of glucagon‐like peptide‐1 receptors: Alternative approaches for treatment of Type 2 diabetes

High Glucose-Induced Glucagon Resistance and Membrane Distribution of GCGR Revealed by Super-Resolution Imaging